Evidence map›Paper›PMID 41200659›Full record

ArticleCureus2025

Limb-Girdle Muscular Dystrophy Type 2B and Morbihan Disease: A Case Report With an Atypical Presentation.

Fernando Briceño Moya, Ana Belen Hernández Hernández, Diana Karina Delgado Carmona

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fernando Briceño MoyaInternal Medicine, UMAE Hospital de Especialidades "Dr. Antonio Fraga Mouret," Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, MEX.
Ana Belen Hernández HernándezInternal Medicine, UMAE Hospital de Especialidades "Dr. Antonio Fraga Mouret," Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, MEX.
Diana Karina Delgado CarmonaInternal Medicine, UMAE Hospital de Especialidades "Dr. Antonio Fraga Mouret," Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, MEX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report presents a 38-year-old man with no significant medical history who was referred to the Internal Medicine Department due to dermatosis and muscle weakness. A multidisciplinary diagnostic approach was initiated, including laboratory, imaging, and even histopathological studies. No definitive diagnosis was obtained. During the diagnostic process, the patient's clinical course was torturous, with evidence of increasing muscle weakness and inability to walk. Due to the lack of a definitive diagnosis, empirical treatment with systemic steroids was initiated, with no clinical evidence of improvement. After ruling out a neoplastic or autoimmune cause, a molecular panel for muscular dystrophies was performed, which identified NM_003494 (DYSF_v001): c.1382T>C; p.(Ile461Thr), a clinically pathogenic and heterozygous variant. This led to the diagnosis of limb-girdle muscle dystrophy type 2B with no evidence of association with dermatosis, consistent with Morbihan disease. Molecular diagnosis was crucial for an accurate diagnosis and thus enabled the implementation of therapeutic strategies aimed at improving the patient's quality of life. Muscular dystrophy type 2B is a disease that still lacks specific treatment and can progress to the point of disability. The patient was fully informed about the progression and prognosis of muscular dystrophy and was referred for physical rehabilitation with the goal of delaying permanent disability. Regarding Morbihan disease, the patient received the prescribed treatment for eight months, with notable improvement in edema and dermatological lesions.

Indexed as

limb-girdle muscular dystrophymorbihan diseasepersistent edemapoor steroid responseprogressive weakness

Identifiers

PMID41200659
PMCPMC12588670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.